Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Invitro InternationalIVRO FCF Margin % is 3.50% as of Jun. 2026. The stock has 1 warning sign investors should review. Among 204 Medical Diagnostics & Research companies, Invitro International ranks worse than 51.96% on this metric.
Invitro International FCF Margin % Historical Data
* Premium members only.
The historical data trend for Invitro International's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Invitro International's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invitro International FCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Invitro International's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Invitro International's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invitro International (IVRO) has a FCF Margin % of 3.50% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Invitro International and its competitors. According to the industry distribution chart, Invitro International ranks #106 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 52%.
Is Invitro International's FCF Margin % too high?
Invitro International's current FCF Margin % is 3.50%. The Medical Diagnostics & Research industry median FCF Margin % is 0.48. Invitro International's value of 3.50% is 636.8% above this industry median. Based on the distribution chart, Invitro International ranks #106 out of 204 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint.
How does Invitro International's FCF Margin % compare to IDTA and FUNI?
According to the Medical Diagnostics & Research industry distribution chart, Invitro International ranks #106 out of 204 companies for FCF Margin %. This places Invitro International in the lower half of its industry. The industry median FCF Margin % is 0.48. Invitro International's value of 3.50% is 636.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Diagnostics & Research company?
The median FCF Margin % among Medical Diagnostics & Research companies is 0.48, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Invitro International's current FCF Margin % of 3.50% is 636.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Invitro International and its competitors. For the Medical Diagnostics & Research industry, the median FCF Margin % is 0.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Invitro International's current FCF Margin % is 3.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invitro International stock overvalued right now?
Based on GuruFocus' analysis, Invitro International (IVRO) is currently considered Fairly Valued. The stock's GF Value™ is $0.06, compared to a current price of $0.06 — trading right at its estimated fair value. The current FCF Margin % is 3.50% and 636.8% above the Medical Diagnostics & Research industry median of 0.48. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Invitro International (IVRO), the current FCF Margin % is 3.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Invitro International is a provider of non-animal testing methods. The company develops and commercializes test kits and laboratory services. Its testing technologies are designed to produce data regarding corrosivity, or ocular/dermal irritation, which correlate with animal and human test results. Its products and services include Irritection, Corrositex, and Lab Services. The company provides its products to various industries such as cosmetics, personal care, household products, textiles, pharmaceuticals, chemicals, and hazardous waste transportation. The majority of its revenue is generated from the United States and it also exports to other countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IVRO has been successfully added to your 
